Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Second Quarter Net Product Revenues Expected to be Approximately $20 Million CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid ® (concentrate of proteolytic enzymes enriched in Bromelain)
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the UBS Virtual Global
Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019 Positive Cash Flow for the Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and
CAMBRIDGE, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2020 financial results and business
CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our employees and
CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 19 th Annual Needham
First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty Regarding Impact of COVID-19 CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in
Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30am Eastern Standard Time CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced
CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 40 th Annual Cowen
